Systemic light chain amyloidosis
V Sanchorawala - New England Journal of Medicine, 2024 - Mass Medical Soc
Key Points Systemic Light Chain Amyloidosis Immunoglobulin light chain (AL) amyloidosis
is a rare disease that occurs when a plasma cell disorder produces monoclonal light chains …
is a rare disease that occurs when a plasma cell disorder produces monoclonal light chains …
Management of AL amyloidosis in 2020
In amyloid light chain (AL) amyloidosis, a small B-cell clone, most commonly a plasma cell
clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the …
clone, produces monoclonal light chains that exert organ toxicity and deposit in tissue in the …
2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA), the European Society for Therapeutic …
AR Lyon, T Lopez-Fernandez, LS Couch… - European Heart …, 2022 - academic.oup.com
ESC Guidelines e341 (1) the specific situation of the patient. In this respect, it is specified
that, unless otherwise provided for by national regulations, offlabel use of medication should …
that, unless otherwise provided for by national regulations, offlabel use of medication should …
2023 ACC expert consensus decision pathway on comprehensive multidisciplinary care for the patient with cardiac amyloidosis: a report of the American College of …
Writing Committee, MM Kittleson, FL Ruberg… - Journal of the American …, 2023 - jacc.org
The systemic amyloidoses are a broad spectrum of diseases that result from misfolding of
proteins that aggregate into b-sheet amyloid fibrils. Over 35 amyloidogenic precursor …
proteins that aggregate into b-sheet amyloid fibrils. Over 35 amyloidogenic precursor …
Diagnosis and treatment of cardiac amyloidosis: a position statement of the ESC Working Group on Myocardial and Pericardial Diseases
P Garcia-Pavia, C Rapezzi, Y Adler, M Arad… - European heart …, 2021 - academic.oup.com
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
Diagnosis and treatment of cardiac amyloidosis. A position statement of the European Society of Cardiology W orking G roup on M yocardial and P ericardial D …
P Garcia‐Pavia, C Rapezzi, Y Adler… - European journal of …, 2021 - Wiley Online Library
Cardiac amyloidosis is a serious and progressive infiltrative disease that is caused by the
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
deposition of amyloid fibrils at the cardiac level. It can be due to rare genetic variants in the …
Systemic amyloidosis from A (AA) to T (ATTR): a review
E Muchtar, A Dispenzieri, H Magen… - Journal of internal …, 2021 - Wiley Online Library
Systemic amyloidosis is a rare protein misfolding and deposition disorder leading to
progressive organ failure. There are over 15 types of systemic amyloidosis, each caused by …
progressive organ failure. There are over 15 types of systemic amyloidosis, each caused by …
ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: part 1 of 2—evidence base …
S Dorbala, Y Ando, S Bokhari… - Circulation …, 2021 - Am Heart Assoc
Sharmila Dorbala, MD, MPH, FASNC, Chair*; Yukio Ando, MD, PhD†; Sabahat Bokhari,
MD‡; Angela Dispenzieri, MD § ; Rodney H. Falk, MD*; Victor A. Ferrari, MD∥; Marianna …
MD‡; Angela Dispenzieri, MD § ; Rodney H. Falk, MD*; Victor A. Ferrari, MD∥; Marianna …
Systemic immunoglobulin light chain amyloidosis
G Merlini, A Dispenzieri, V Sanchorawala… - Nature reviews Disease …, 2018 - nature.com
Systemic immunoglobulin light chain amyloidosis is a protein misfolding disease caused by
the conversion of immunoglobulin light chains from their soluble functional states into highly …
the conversion of immunoglobulin light chains from their soluble functional states into highly …
A new staging system for cardiac transthyretin amyloidosis
JD Gillmore, T Damy, M Fontana… - European heart …, 2018 - academic.oup.com
Aims Cardiac transthyretin (ATTR) amyloidosis is an increasingly recognized, progressive,
and fatal cardiomyopathy, the natural history of which remains unclear. We sought to …
and fatal cardiomyopathy, the natural history of which remains unclear. We sought to …